Beauty Health Stock Soars 52%: A $1.19 Earnings Beat Nobody Expected

Beauty Health stock soared 51.8% on Friday, November 6, 2026, closing at $15.71 after the company behind Hydrafacial reported a loss far smaller than Wall Street expected. SkinHealth Systems (NASDAQ: SKIN) lost $0.14 per share in the third quarter against a consensus forecast of a $1.33 loss — a $1.19 beat — and the surprise sent trading volume to nearly ten times its normal level.

What happened

SkinHealth Systems, the Long Beach, California company home to the flagship Hydrafacial brand, released its third-quarter results on Thursday, November 5, after the close. Revenue came in at $69.2 million, ahead of the $67.97 million analysts expected and near the top of the company's own $65 million to $70 million guidance range.

The headline numbers looked very different from a year earlier. The net loss narrowed to $0.9 million from $11.0 million in the same quarter last year. Gross margin rose to 68.2% from 64.6%, adjusted gross margin reached 71.8%, and adjusted EBITDA climbed to $13.4 million from $8.9 million a year ago. The company also delivered positive GAAP operating income for a second straight quarter, according to its earnings call.

On Friday the market repriced the stock in one session. Shares rose $5.36 from a $10.35 close to $15.71, with 433,975 shares changing hands compared with an average volume of just 44,874. The stock remains well below its 52-week high of $34.80, and it is still down about 43% for the year, which helps explain why a single better-than-feared quarter had such an outsized effect.

Why it is blowing up

Three things collided. First, expectations were extremely low: analysts were braced for a $1.33 per-share loss, so a $0.14 loss read as a major upside surprise. Second, the underlying trend improved — revenue fell 2.1% year over year, a much smaller decline than the 7.8% drop in the second quarter and the 6.7% drop in the first, and global consumables sales returned to growth, up 1.2% to $50.4 million. Third, management raised the outlook, lifting full-year adjusted EBITDA guidance to $48 million to $50 million, from $39 million to $46 million previously, while narrowing the sales range to $281 million to $287 million.

Social attention followed the price. Tracking of stock mentions on X showed discussion of Beauty Health surging by more than 3,100% over 24 hours as the move topped trending-ticker lists — the classic pattern of a small, heavily doubted stock suddenly back on traders' screens.

Key facts

• Stock move: +51.79% on Friday, November 6, to $15.71 from $10.35, on volume of 433,975 shares versus a 44,874 average.
• Earnings: Loss of $0.14 per share versus a $1.33 consensus loss — a $1.19 beat.
• Revenue: $69.2 million, down 2.1% year over year, versus $67.97 million expected.
• Profitability: Net loss narrowed to $0.9 million from $11.0 million; adjusted EBITDA rose to $13.4 million from $8.9 million.
• Guidance: Full-year 2026 sales of $281 million to $287 million and adjusted EBITDA raised to $48 million to $50 million.
• Balance sheet: The company repaid its $103.2 million 2026 convertible notes as planned and ended the quarter with $112.4 million in cash.

Sources: SkinHealth Systems Q3 2026 results (GlobeNewswire), Transcript Daily earnings report, November 7, Motley Fool earnings call transcript, MarketBeat SKIN data, AltIndex trending tickers on X.

What still worries investors

This was a beat against low expectations, not a return to growth overall. Equipment remains the headwind: delivery-system revenue fell 9.9%, with 798 systems placed versus 875 a year earlier, and revenue in Europe, the Middle East and Africa declined 11.7%. Management also cautioned that the third quarter benefited from a one-time tariff refund and that fourth-quarter margins are expected to moderate. The company is still loss-making on a trailing basis, and about $250 million of convertible debt due in late 2028 remains to be addressed, which management expects to tackle in 2027.

The turnaround plan leans on getting more from the installed base: a new HydraClear booster launched in October, a HydraScalp relaunch, SkinStylus consumables up 39% year over year, a new U.S. rental program to lower the upfront cost for providers, and a next-generation Hydrafacial platform targeted for 2028.

What's next

The next test is whether Friday's repricing holds when markets reopen on Monday and whether the raised EBITDA range survives a softer-margin fourth quarter. Analysts on average still rate the stock a Hold, with a consensus price target of $18.00, according to MarketBeat data. For now, the story is simple: a stock priced for a much worse quarter got a much better one, and traders noticed all at once. This report is news coverage, not financial advice.

FAQ

Why did Beauty Health (SKIN) stock rise 52%?

It rose 51.79% on Friday, November 6, 2026, after third-quarter earnings beat expectations by a wide margin — a $0.14 per-share loss versus a $1.33 consensus loss — on nearly ten times normal trading volume.

What were Beauty Health's Q3 2026 results?

Revenue was $69.2 million, down 2.1% year over year but above the $67.97 million expected, the net loss narrowed to $0.9 million, and adjusted EBITDA rose to $13.4 million.

Did Beauty Health raise its guidance?

Yes. It raised full-year 2026 adjusted EBITDA guidance to $48 million to $50 million and narrowed the sales outlook to $281 million to $287 million.

What risks remain for SKIN stock?

Equipment placements are still falling, EMEA revenue declined 11.7%, fourth-quarter margins are expected to moderate after a one-time tariff benefit, and about $250 million of convertible debt due in 2028 still needs to be addressed.